顺铂/谷胱甘肽(Cisplatin/Glutathione) - 在研适应症：肿瘤_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Glutathione/cisplatin、Glutoxim

+ [1]

靶点-

作用机制

DNA烷化剂

治疗领域

肿瘤

在研适应症

肿瘤

非在研适应症

乳腺癌白血病骨髓增生异常综合征+ [3]

原研机构

Cellectar Biosciences, Inc.

在研机构

Sleep Number Labs

非在研机构

Cellectar Biosciences, Inc.

最高研发阶段批准上市

首次获批日期

俄罗斯 (2001-07-03),

肿瘤

最高研发阶段(中国)-

特殊审评-

登录后查看首次获批时间轴

结构

分子式Cl2H6N2Pt

InChIKeyWCLAIRSNZFYZAT-UHFFFAOYSA-N

CAS号15663-27-1

查看全部结构式(2)

关联

4

项与顺铂/谷胱甘肽相关的临床试验

NCT00499122 / Completed临床2期IIT

Phase II Study of Neoadjuvant Treatment With NOV-002 in Combination With Doxorubicin and Cyclophosphamide Followed by Docetaxel in Patients With Stages IIB-IIIC Breast Cancer

RATIONALE: Oxidized glutathione (NOV-002) may stimulate the immune system in different ways and stop tumor cells from growing. Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving NOV-002 together with chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
PURPOSE: This phase II trial is studying how well giving oxidized glutathione (NOV-002) together with doxorubicin and cyclophosphamide followed by docetaxel works in treating women with newly diagnosed stage II or stage III breast cancer.

开始日期2007-06-04

申办/合作机构

University of Miami

NCT00347412 / Completed临床3期

Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)

The purpose of this clinical trial is to find out whether or not the combination of NOV-002 with chemotherapy (paclitaxel and carboplatin) is better at improving overall survival time when compared to chemotherapy alone in people with non-small cell lung cancer (NSCLC).
Earlier clinical trials in NSCLC showed that patients treated with NOV-002 in combination with chemotherapy had a better response (their tumors got smaller in one United States Phase 1/2 trial) than patients who received chemotherapy alone; and in two Phase 2 trials done in Russian patients, at the end of one year, patients treated with NOV-002 with chemotherapy had a better survival rate than patients who did not receive NOV-002 with their chemotherapy.

开始日期2006-11-01

申办/合作机构

Cellectar Biosciences, Inc.

NCT00345540 / Completed临床2期

Phase 2 Trial of NOV-002 With Carboplatin in Women With Recurrent and Platinum Resistant Tumors of Mullerian Origin

The purpose of this trial is to determine the tumor response rate of NOV-002 plus carboplatin in a cohort of women with platinum resistant cancer of ovarian origin.

开始日期2006-07-01

申办/合作机构

Cellectar Biosciences, Inc.

[+2]

100 项与顺铂/谷胱甘肽相关的临床结果

登录后查看更多信息

100 项与顺铂/谷胱甘肽相关的转化医学

登录后查看更多信息

100 项与顺铂/谷胱甘肽相关的专利（医药）

登录后查看更多信息

59

项与顺铂/谷胱甘肽相关的文献（医药）

2022-06-01·Cell and Tissue Biology

Sigma-1 Receptor Ligands Chlorpromazine and Trifluoperazine Attenuate Ca2+ Responses in Rat Peritoneal Macrophages

Article

作者: Antonov, V G ; Milenina, L S ; Krutetskaya, Z I ; Krutetskaya, N I

Sigma-1 receptors are ubiquitous multifunctional ligand-regulated molecular chaperones in the endoplasmic reticulum membrane with a unique history, structure, and pharmacological profile. Sigma-1 receptors bind ligands of different chemical structure and pharmacological action and modulate a wide range of cellular processes in health and disease, including Ca²⁺ signaling. To elucidate the involvement of sigma-1 receptors in the processes of Ca²⁺ signaling in macrophages we studied the effect of sigma-1 receptor ligands, phenothiazine neuroleptics chlorpromazine and trifluoperazine, on Ca²⁺ responses induced by inhibitors of endoplasmic Ca²⁺-ATPases thapsigargin and cyclopiazonic acid, as well as by disulfide-containing immunomodulators Glutoxim and Molixan in rat peritoneal macrophages. Using Fura-2AM microfluorimetry we showed for the first time that chlorpromazine and trifluoperazine inhibit both phases of Ca²⁺ responses induced by Glutoxim, Molixan, thapsigargin, and cyclopiazonic acid in rat peritoneal macrophages. The data obtained indicate the participation of sigma-1 receptors in a complex signaling cascade caused by Glutoxim or Molixan and leading to an increase in intracellular Ca²⁺ concentration in macrophages. The results also indicate the involvement of sigma-1 receptors in the regulation of store-dependent Ca²⁺entry in macrophages.

2020-12-01·Bulletin of Experimental Biology and Medicine4区 · 医学

Human Diploid Fibroblast Cell Lines — a Model System for Studying Immunodulatory Properties of Modern Immunobiological Drugs and Viruses

4区 · 医学

Article

作者: Konyuschko, O I ; Kozhevnikova, T N ; Ishmuhametov, A A ; Ivanova, A L ; Ozherelkov, S V ; Sanin, A V ; Sotskova, S E ; Vorovich, M F

The immunomodulatory properties of immunobiological drugs Glutoxim and Phosprenyl we well as vesicular stomatitis virus and inactivated tick-borne encephalitis vaccine virus were studied using human diploid fibroblast cell line from the collection of M. P. Chumakov Federal Research Center for Research and Development of Immunobiological Products. All tested preparations exhibited immunomodulatory activity in human diploid fibroblast cell line. Glutoxim in doses of 0.1 and 0.25 μg/ml stimulated production of IL-6 and IL-10 during 24-48 h of culturing, but did not stimulate production of IL-1β. Phosprenyl, on the contrary, increased production of IL-1β and the levels of IL-6 and IL-10. Vesicular stomatitis virus stimulated the production of IL-1β, IL-6, and IL-10, while inactivated tick-borne encephalitis vaccine virus stimulated the production of cytokines IL-8 and IL-18. Immunomodulatory activity of inactivated tick-borne encephalitis vaccine virus was first demonstrated in the in vitro system.

2020-01-01·Doklady Biochemistry and Biophysics4区 · 生物学

Neuroleptic Chlorpromazine Modulates Ca2+ Responses in Macrophages

4区 · 生物学

Article

作者: Nozdrachev, A D ; Krutetskaya, Z I ; Milenina, L S ; Antonov, V G

Using Fura-2AM microfluorimetry, we have shown for the first time that sigma-1 receptor antagonist neuroleptic chlorpromazine significantly inhibits glutoxim- and molixan-induced Ca²⁺ responses and Ca²⁺ responses induced by endoplasmic reticulum Са²⁺-ATPase inhibitors thapsigargin and cyclopiazonic acid in rat peritoneal macrophages. The results suggest the involvement of sigma-1 receptors in the signaling cascade induced by glutoxim or molixan and leading to intracellular Ca²⁺ concentration increase and in the regulation of store-dependent Ca²⁺ entry in macrophages.

100 项与顺铂/谷胱甘肽相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L01XY	DB05393

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
肿瘤	俄罗斯	Sleep Number Labs	2001-07-03

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
非小细胞肺癌	临床2期	加拿大	Cellectar Biosciences, Inc.	2006-11-01
非小细胞肺癌	临床2期	罗马尼亚	Cellectar Biosciences, Inc.	2006-11-01
非小细胞肺癌	临床1期	乌克兰	Cellectar Biosciences, Inc.	2006-11-01
非小细胞肺癌	临床1期	英国	Cellectar Biosciences, Inc.	2006-11-01
非小细胞肺癌	临床1期	以色列	Cellectar Biosciences, Inc.	2006-11-01
非小细胞肺癌	临床1期	美国	Cellectar Biosciences, Inc.	2006-11-01
非小细胞肺癌	临床1期	西班牙	Cellectar Biosciences, Inc.	2006-11-01
非小细胞肺癌	临床1期	瑞士	Cellectar Biosciences, Inc.	2006-11-01
非小细胞肺癌	临床1期	波兰	Cellectar Biosciences, Inc.	2006-11-01
非小细胞肺癌	临床1期	俄罗斯	Cellectar Biosciences, Inc.	2006-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00499122 (Pubmed \| Breast Cancer Res)	临床2期	HER2 阴性乳腺癌新辅助	41	NOV-002	(窪襯夢壓獵糧積築窪膚) = 鹽積夢願鏇衊鏇鑰鏇夢鬱範窪醖膚構鑰鏇廠選 (蓋糧鹽蓋遞鹹襯餘淵鑰 )	-	2012-02-01
ASCO2006	临床1/2期	非小细胞肺癌一线	44	NOV-002 + carboplatin and paclitaxel (i.m.)	(築網繭網襯壓鏇蓋艱製) = 艱憲鏇夢壓廠醖築積蓋構襯獵醖廠築窪鏇壓積 (夢觸製鑰餘艱範鑰積遞 ) 更多	积极	2006-06-20
				NOV-002 + carboplatin and paclitaxel (s.c.)	(築網繭網襯壓鏇蓋艱製) = 鬱醖繭網願觸淵繭鬱醖構襯獵醖廠築窪鏇壓積 (夢觸製鑰餘艱範鑰積遞 ) 更多
ChiCTR1900024488 (ESMO2020) 人工标引	临床1期	实体瘤	9	cisplatin 40mg/m2+niraparib 100mg+sintilimab 200mg	(獵艱構壓憲壓醖糧鑰遞) = 鑰壓獵夢醖壓廠艱積簾夢製簾鏇繭選範壓築艱 (壓齋製窪願壓鹹鏇淵鬱 )	积极	2020-09-17
				cisplatin 60mg/m2+niraparib 100mg+sintilimab 200mg	(獵艱構壓憲壓醖糧鑰遞) = 繭餘遞襯鹽網壓鬱夢構夢製簾鏇繭選範壓築艱 (壓齋製窪願壓鹹鏇淵鬱 )
NCT03043872 (CASPIAN, Pubmed) 人工标引	临床3期	广泛期小细胞肺癌一线	34	carboplatin/cisplatin+durvalumab	(衊齋製鹽齋網鹹餘構構) = 繭鬱壓範鏇膚齋網夢鹹獵鏇襯鑰醖鹽鏇選壓簾 (衊簾觸衊製餘觸憲選繭 ) 更多	积极	2021-06-01
				carboplatin/cisplatin	(衊齋製鹽齋網鹹餘構構) = 鏇襯衊窪簾鹽鑰繭糧鏇獵鏇襯鑰醖鹽鏇選壓簾 (衊簾觸衊製餘觸憲選繭 ) 更多
NCT04649476 (ESMO_IO2022) 人工标引	临床2期	口腔鳞状细胞癌新辅助	60	camrelizumab 200 mg	(簾膚襯鹽觸願顧衊艱鏇) = 願築鹽壓網衊鹹鹽鬱鏇窪廠艱築獵願顧餘淵壓 (淵夢糧鑰鹽繭鑰網選鬱, 3.3 ~ 30.0) 更多	积极	2022-12-08
				camrelizumab 200 mg+docetaxel 75 mg/m2+cisplatin 75 mg/m2+5-fluorouracil 750 mg/m2	(簾膚襯鹽觸願顧衊艱鏇) = 網醖衊顧觸範壓衊構壓窪廠艱築獵願顧餘淵壓 (淵夢糧鑰鹽繭鑰網選鬱, 70.0 ~ 96.7) 更多
ERS2014	N/A	-	-	Glutoxim	鑰遞糧獵艱範衊糧觸衊(築選淵製繭網積鑰艱鬱) = 壓積鑰壓繭膚鏇艱憲鹽夢築範夢襯醖網膚壓壓 (遞壓窪鹹鑰築醖餘夢鬱 )	-	2014-09-01
WCLC2013	N/A	晚期肺非小细胞鳞癌一线	172	Cixutumumab 20 mg/kg + Pemetrexed 500 mg/m2 + Cisplatin 75 mg/m2	(餘鹽襯餘衊積廠顧窪襯) = 壓膚製觸糧鏇範艱繭繭蓋廠衊窪鏇製願網鹹網 (構範餘鹽鏇製夢製遞壓 ) 更多	不佳	2013-10-30
				Pemetrexed + Cisplatin	(餘鹽襯餘衊積廠顧窪襯) = 夢蓋淵範鑰築構醖鹽窪蓋廠衊窪鏇製願網鹹網 (構範餘鹽鏇製夢製遞壓 ) 更多
ASCO2010	临床3期	非小细胞肺癌	903	NOV-002 + paclitaxel + carboplatin	(鹽鬱鹽製願夢範選願積) = 顧鑰鑰鹽觸簾獵襯壓鹹構鏇淵窪範製齋淵夢獵 (壓願淵鬱獵簾餘網築壓 ) 更多	不佳	2010-06-20
				paclitaxel + carboplatin	(鹽鬱鹽製願夢範選願積) = 範鹽顧艱願憲鑰糧壓鏇構鏇淵窪範製齋淵夢獵 (壓願淵鬱獵簾餘網築壓 ) 更多
ACTRN12616001170415 (WCLC2018)	临床1/2期	间皮瘤一线	54	Durvalumab 1125mg + Cisplatin 75mg/m2 + Pemetrexed 500mg/m2	膚壓顧製鑰艱遞襯築遞(選蓋鹹繭窪淵壓顧築獵) = 鏇醖願憲積繭網廠鹽鬱網獵衊範憲簾選築壓艱 (製顧膚選糧壓顧鏇鹽構, 45 ~ 68) 更多	-	2018-09-24
NCT00345540 (CTgov)	临床2期	卵巢癌	15	Carboplatin+NOV-002	(觸構壓選廠衊襯壓顧遞) = 製鏇糧鑰淵網壓艱鏇繭齋淵壓遞憲憲醖鹹願積 (醖憲鬱鬱廠艱蓋範餘鏇, 網鑰遞襯顧壓窪醖願遞 ~ 鏇繭遞艱壓製鑰觸鑰構) 更多	-	2015-03-10